Skip to Content

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

In this MEDtalk, MD and Assistant Professor Paolo Strati present findings from the first-ever clinical trial testing anti-signal regulatory protein-alpha (SIRPα) antibody CC-95251 in combination with Rituximab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

Paolo Strati

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top